<bill session="108" type="s" number="7" updated="2023-01-15T21:34:05Z">
  <state datetime="2003-01-07">REFERRED</state>
  <status>
    <introduced datetime="2003-01-07"/>
  </status>
  <introduced datetime="2003-01-07"/>
  <titles>
    <title type="display">Prescription Drug Benefit and Cost Containment Act of 2003</title>
    <title type="official" as="introduced">A bill to amend title XVIII of the Social Security Act to provide coverage of outpatient prescription drugs under the medicare program and to amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals, and for other purposes.</title>
    <title type="short" as="introduced">Prescription Drug Benefit and Cost Containment Act of 2003</title>
  </titles>
  <sponsor bioguide_id="D000064"/>
  <cosponsors>
    <cosponsor bioguide_id="A000069" joined="2003-01-07"/>
    <cosponsor bioguide_id="B000711" joined="2003-01-09"/>
    <cosponsor bioguide_id="B001210" joined="2003-02-26"/>
    <cosponsor bioguide_id="C001041" joined="2003-01-07"/>
    <cosponsor bioguide_id="C001042" joined="2003-01-07"/>
    <cosponsor bioguide_id="D000596" joined="2003-01-07"/>
    <cosponsor bioguide_id="D000388" joined="2003-01-09"/>
    <cosponsor bioguide_id="D000563" joined="2003-01-07"/>
    <cosponsor bioguide_id="J000177" joined="2003-01-07"/>
    <cosponsor bioguide_id="K000105" joined="2003-01-07"/>
    <cosponsor bioguide_id="L000123" joined="2003-01-07"/>
    <cosponsor bioguide_id="L000174" joined="2003-01-07"/>
    <cosponsor bioguide_id="L000261" joined="2003-01-07"/>
    <cosponsor bioguide_id="M000702" joined="2003-01-07"/>
    <cosponsor bioguide_id="N000032" joined="2003-04-02"/>
    <cosponsor bioguide_id="R000122" joined="2003-01-07"/>
    <cosponsor bioguide_id="R000146" joined="2003-01-07"/>
    <cosponsor bioguide_id="R000361" joined="2003-01-07"/>
    <cosponsor bioguide_id="S000064" joined="2003-01-07"/>
    <cosponsor bioguide_id="S000148" joined="2003-01-07"/>
    <cosponsor bioguide_id="S000770" joined="2003-01-07"/>
  </cosponsors>
  <actions>
    <action datetime="2003-01-07">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2003-01-07">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR 1/9/2003 S134"/>
    </action>
    <action datetime="2003-01-07" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative procedure"/>
    <term name="Ambulatory care"/>
    <term name="Armed Forces and National Security"/>
    <term name="Auditing"/>
    <term name="Business records"/>
    <term name="Canada"/>
    <term name="Child health"/>
    <term name="Civil Rights and Liberties, Minority Issues"/>
    <term name="Commerce"/>
    <term name="Communication in medicine"/>
    <term name="Conflict of interests"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Consent decrees"/>
    <term name="Consumer education"/>
    <term name="Consumer organizations"/>
    <term name="Continuum of care"/>
    <term name="Crime and Law Enforcement"/>
    <term name="Department of Health and Human Services"/>
    <term name="District of Columbia"/>
    <term name="Drug advertising"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Drug interactions"/>
    <term name="Drug therapy"/>
    <term name="Drugs"/>
    <term name="Economics and Public Finance"/>
    <term name="Education"/>
    <term name="Electronic data interchange"/>
    <term name="Emergency medicine"/>
    <term name="Employee benefit plans"/>
    <term name="Employee health benefits"/>
    <term name="Families"/>
    <term name="Federal Trade Commission"/>
    <term name="Federal advisory bodies"/>
    <term name="Federal aid to health facilities"/>
    <term name="Fees"/>
    <term name="Finance and Financial Sector"/>
    <term name="Fines (Penalties)"/>
    <term name="Fraud"/>
    <term name="Generic drugs"/>
    <term name="Government Operations and Politics"/>
    <term name="Government trust funds"/>
    <term name="Governmental investigations"/>
    <term name="Grants-in-aid"/>
    <term name="Health care fraud"/>
    <term name="Health education"/>
    <term name="Health information systems"/>
    <term name="Health insurance"/>
    <term name="Health insurance continuation"/>
    <term name="Health maintenance organizations"/>
    <term name="Health services administration"/>
    <term name="Home care services"/>
    <term name="Hospitals"/>
    <term name="Housing and Community Development"/>
    <term name="Immunosuppressive drugs"/>
    <term name="Imports"/>
    <term name="Independent regulatory commissions"/>
    <term name="Information networks"/>
    <term name="Injunctions"/>
    <term name="Intellectual property"/>
    <term name="Judicial opinions"/>
    <term name="Judicial review"/>
    <term name="Kidney diseases"/>
    <term name="Labeling"/>
    <term name="Labor and Employment"/>
    <term name="Law"/>
    <term name="Mail-order business"/>
    <term name="Managed care"/>
    <term name="Marketing"/>
    <term name="Medicaid"/>
    <term name="Medical economics"/>
    <term name="Medical fees"/>
    <term name="Medical records"/>
    <term name="Medical statistics"/>
    <term name="Medicare"/>
    <term name="Medication abuse"/>
    <term name="Medigap"/>
    <term name="Metropolitan areas"/>
    <term name="Patent infringement"/>
    <term name="Patents"/>
    <term name="Patients' rights"/>
    <term name="Pharmaceutical research"/>
    <term name="Pharmacies"/>
    <term name="Prescription pricing"/>
    <term name="Quality control"/>
    <term name="Rebates"/>
    <term name="Restrictive trade practices"/>
    <term name="Retiree health benefits"/>
    <term name="Right of petition"/>
    <term name="Right of privacy"/>
    <term name="Rural health"/>
    <term name="Science, Technology, Communications"/>
    <term name="Social Welfare"/>
    <term name="Standards"/>
    <term name="Surveys"/>
    <term name="Technological innovations"/>
    <term name="Territories (U.S.)"/>
    <term name="Transplantation of organs, tissues, etc."/>
    <term name="Urban affairs"/>
    <term name="Veterans' benefits"/>
    <term name="Veterans' medical care"/>
  </subjects>
  <amendments/>
  <summary date="2006-11-28T17:35:40Z" status="Introduced in Senate">Prescription Drug Benefit and Cost Containment Act of 2003 - Amends title XVIII (Medicare) of the Social Security Act (SSA) to establish: (1) a Medicare Outpatient Prescription Drug Benefit Program under new part D; (2) a Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund; and (3) a Medicare Prescription Drug Advisory Committee.Provides for: (1) part D benefits under Medicare+Choice plans under Medicare part C (Medicare+Choice); and (2) Medicare cost-sharing and other assistance for low-income individuals.Revises requirements for Medicare supplemental insurance policy (Medigap) benefit packages to conform to changes made by this Act.Provides for coverage of immunosuppressive drugs for all Medicare beneficiaries under Medicare part B (Supplementary Medical Insurance).Directs the Secretary of Health and Human Services to study and report to Congress on the feasibility and advisability of establishing a uniform format for pharmacy benefit cards provided to beneficiaries.Expands the membership and duties of the Medicare Payment Advisory Commission (MEDPAC).Amends the Federal Food, Drug, and Cosmetic Act to revise provisions concerning the timing of generic drug availability.Requires applicants (pharmaceutical companies) to register their patents with the Food and Drug Administration (FDA) within 30 days of approval (or issuance for subsequently issued patents). Makes failure to timely register a bar to civil actions for patent infringement.Requires applications for new drugs (NDA) or abbreviated new drug applications (ANDA) which rely upon investigations not conducted by or for the applicant and which concern a patent that claims both the drug and a method of use or more than one method of use to include a certification on a claim-by-claim basis that the patent is invalid or will not be infringed (known as a Paragraph IV filing/certification) by the new drug's (generic) manufacture and a statement regarding the method(s) of use claim.Prohibits (for subsequently issued patents) an extension of the 30-month stay of FDA approval for any new drug where an ANDA or NDA contains a Paragraph IV filing/certification and the patent holder indicates an intention to bring a patent infringement suit against the new (generic) drug's manufacturer. Makes failure to timely file a civil action for infringement a bar to later action.Requires the first generic applicant with a Paragraph IV filing to forfeit the 180 day marketing exclusivity period to a subsequent generic applicant if the first generic applicant engages in certain behaviors (forfeiture events) which delay or prevent the marketing of the generic drug.Adds provisions on importation of prescription drugs and pediatric labeling of drugs and biological products.</summary>
</bill>
